By thirty-nine, she was being told she’d probably need a third procedure — and potentially more after that — unless something changed. Nobody in her care team had mentioned dupilumab, the biologic medication recently approved specifically for her condition. Beth wasn’t failing surgery. Surgery was failing Beth, because the underlying disease had never actually been controlled.
Nasal polyps represent one of the clearest examples in otolaryngology of a condition where the surgical reflex — operate, remove, wait for them to come back, operate again — was practiced for decades as the primary management strategy while the underlying inflammatory disease went largely untreated. The result is a cycle that perpetuates itself: surgery clears the polyps, the uncontrolled inflammatory environment generates new ones, surgery clears them again.
Each cycle carries cumulative risk, progressive mucosal scarring, and eventually impaired surgical anatomy that makes subsequent procedures more difficult and less effective.
What follows covers nasal polyps comprehensively — their pathogenesis, the inflammatory biology driving their formation and recurrence, the evidence-based medical management that has transformed outcomes in the biologic era, the role of surgery in a combined management strategy, and the practical approach to living with a chronic condition that requires ongoing management rather than a one-time fix.
What Nasal Polyps Actually Are
Nasal polyps are benign, teardrop-shaped outgrowths of the nasal and sinus mucosa — pale, glistening masses protruding from the mucosal surface, typically originating in the ethmoid sinuses and growing through the ostiomeatal complex into the nasal cavity. Despite the name “polyps” (which suggests a growthlike abnormality), they aren’t tumors. No autonomous growth potential, no malignant risk.
They’re edematous, inflamed, reorganized mucosal tissue, driven by chronic inflammation to proliferate and grow in a pattern that is both a consequence and a perpetuating factor of the underlying inflammatory disease.
Histologically, the most common type of nasal polyp (eosinophilic polyps in CRS with nasal polyps) consists of edematous connective tissue stroma containing abundant eosinophils, mast cells, and plasma cells, covered by respiratory epithelium. The eosinophilic infiltration reflects the type 2 immune-dominant inflammatory environment generating polyp formation. There’s virtually no smooth muscle in nasal polyps (unlike intestinal polyps), which explains why they’re soft, compressible, and not painful under gentle palpation.
Their characteristic pale, translucent, or slightly grayish appearance reflects the edematous, protein-rich stroma and the absence of significant vascularity compared to normal nasal mucosa.
The anatomy of polyp origin matters clinically. Most polyps originate in the ethmoid sinuses — particularly the anterior ethmoid cells — and grow downward through the middle meatus into the nasal cavity. As they enlarge, they block the ostiomeatal complex (the common drainage pathway for the maxillary, frontal, and anterior ethmoid sinuses), the airway, and eventually the olfactory cleft.
Bilateral nasal polyps are far more common than unilateral — unilateral polyps are a red flag warranting tissue diagnosis to exclude sinonasal malignancy (inverted papilloma, which can look like an inflammatory polyp but carries malignant potential, is the most important differential for unilateral polyps). The distribution pattern on endoscopy — bilateral, arising from the middle meatus, pale and gelatinous — is characteristic of inflammatory CRSwNP.
The Inflammatory Biology Driving Polyp Formation
The molecular biology of nasal polyp formation has been substantially elucidated over the past two decades, driven by sophisticated immunological tools and, importantly, by the development of targeted biologic therapies whose effectiveness has validated the proposed mechanisms. This biology isn’t merely academic — it directly explains why specific treatments work, why generic anti-inflammatory approaches often don’t, and why some patients get more aggressive and recurrent disease than others.
The dominant inflammatory pathway in eosinophilic CRSwNP involves type 2 helper T (Th2) cell-mediated immune activation, with the key cytokines being IL-4, IL-5, and IL-13. IL-4 and IL-13 act through a shared receptor (IL-4Rα) to drive B cell class-switching to IgE production (creating the allergic immunological milieu), goblet cell hyperplasia (increasing mucus production), and mucosal epithelial barrier disruption (increasing permeability to allergens and irritants).
IL-5 drives eosinophil production in the bone marrow, activation, survival, and tissue retention — the key cytokine responsible for the dense eosinophilic infiltrate of polyp tissue. Thymic stromal lymphopoietin (TSLP) and IL-33 — “alarmin” cytokines produced by the damaged epithelium in response to environmental insults — initiate this Th2 cascade by activating innate lymphoid cells type 2 (ILC2s) and dendritic cells.
The tissue eosinophilia of polyp tissue isn’t merely a marker of inflammation. It actively drives tissue remodeling. Eosinophil granule proteins (major basic protein, eosinophil cationic protein, eosinophil peroxidase) directly damage the epithelium, activate mast cells, promote fibroblast activity, and contribute to the submucosal edema that characterizes polyp tissue. Eosinophil extracellular traps (EETs) — a process analogous to neutrophil NETs — contribute to mucus trapping and epithelial injury.
The net effect of sustained eosinophilic inflammation is progressive mucosal remodeling — edema, goblet cell hyperplasia, basement membrane thickening, and ultimately polyp formation as the remodeled mucosa herniates through natural structural weaknesses in the lamina propria.
Staphylococcus aureus plays a particularly important role in a subset of CRSwNP patients. S. aureus colonizes the polyp surface and produces superantigens — proteins that non-specifically activate a large fraction of T cells and drive massive cytokine release, including IL-5 and IgE production. S. aureus-related superantigen drive correlates with more severe type 2 inflammation, higher tissue eosinophilia, higher total IgE, and worse clinical outcomes.
S. aureus biofilms on polyp surfaces protect the bacteria from antibiotic clearance and allow persistent superantigen production — a mechanism that helps explain why some patients have particularly severe and refractory disease.
AERD: The Aspirin-Exacerbated Respiratory Disease Triad
Aspirin-exacerbated respiratory disease (AERD) — historically called Samter’s triad or aspirin triad — is a distinct endotype of CRSwNP characterized by the combination of severe nasal polyps, asthma, and hypersensitivity to aspirin and all non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase-1 (COX-1). It affects approximately 5 to 15 percent of asthmatic adults and approximately 25 to 30 percent of patients with severe CRSwNP.
Understanding AERD matters because patients with this endotype have a particularly aggressive polyp phenotype — rapid recurrence after surgery and difficult-to-control asthma — and because specific management approaches (aspirin desensitization, zileuton) are available and effective specifically in AERD.
The pathophysiology involves dysregulation of arachidonic acid metabolism. Normally, arachidonic acid — a membrane phospholipid — is processed both by COX enzymes (producing prostaglandins and thromboxane) and by 5-lipoxygenase (5-LOX, producing leukotrienes). Patients with AERD have constitutively elevated leukotriene production (particularly LTC4, LTD4, and LTE4 — cysteinyl leukotrienes causing mast cell and eosinophil activation, bronchospasm, and mucus production) and reduced prostaglandin E2 (PGE2) production.
PGE2 normally provides a braking signal on mast cells and eosinophils; its deficiency in AERD removes this brake. When COX-1 inhibitors like aspirin or ibuprofen are ingested, they block the COX pathway, shunting even more arachidonic acid toward the already overactive 5-LOX pathway, producing a massive surge in cysteinyl leukotrienes that triggers acute bronchospasm, profuse rhinorrhea, and sometimes systemic anaphylactoid reaction.
Aspirin desensitization — a structured protocol of gradually increasing aspirin doses under medical supervision until tolerance is achieved — can be performed in appropriate AERD patients and produces significant clinical benefits beyond simply allowing aspirin use. Post-desensitization maintenance aspirin therapy (1300 mg daily) reduces polyp burden, reduces the need for rescue oral corticosteroids, and improves asthma control in randomized trials. The mechanism involves downregulation of the baseline cysteinyl leukotriene overproduction rather than simply blocking the acute reaction.
Aspirin desensitization is performed at specialized centers with emergency resources on hand and isn’t appropriate for patients with severe aspirin sensitivity without experience in the protocol.
Biologic Therapies: The Fundamental Change
Dupilumab (Dupixent) — a human monoclonal antibody targeting the IL-4Rα receptor shared by IL-4 and IL-13 — is the most comprehensively studied biologic in CRSwNP, and the first to receive FDA approval (2019) for this indication.
The pivotal SINUS-24 and SINUS-52 trials demonstrated remarkable efficacy: dupilumab-treated patients showed significant reductions in total polyp score (a standardized endoscopic measurement), improvements in nasal obstruction, and dramatic improvements in sense of smell — smell improvement being among the most striking and patient-meaningful outcomes. Approximately 50 to 65 percent of dupilumab-treated patients achieved clinically meaningful improvements across all of these endpoints.
Crucially, dupilumab also significantly improved asthma control in patients with comorbid asthma — consistent with the shared type 2 inflammatory mechanism. Dupilumab is given as a subcutaneous injection every two weeks, and efficacy requires ongoing treatment — polyp recurrence typically follows within months of discontinuation.
Omalizumab (Xolair) — an anti-IgE monoclonal antibody — targets the elevated IgE production characterizing allergic and type 2 inflammatory disease. It received FDA approval for CRSwNP in 2020, based on the POLYP-1 and POLYP-2 trials showing significant reductions in polyp score and symptom burden compared to placebo. Omalizumab is dosed by weight and baseline IgE level, given subcutaneously every 2-4 weeks.
It tends to work best in patients with the highest IgE levels and most evident allergic sensitization — consistent with its mechanism of targeting IgE directly.
Mepolizumab (Nucala) — an anti-IL-5 monoclonal antibody — targets the eosinophil survival and activation cytokine, and received FDA approval for CRSwNP in 2021, based on the SYNAPSE trial. Biologic selection for individual patients depends on comorbidities (dupilumab preferred when comorbid asthma and atopic dermatitis are present), biomarker profile (blood eosinophil count, total IgE), insurance coverage, and patient preference.
The field is evolving rapidly, with head-to-head comparative trials and biomarker-guided selection algorithms under development.
Surgery in the Biologic Era: Redefining the Role of FESS
Effective biologic therapy for CRSwNP doesn’t eliminate the role of functional endoscopic sinus surgery. It redefines it.
The question is no longer “surgery or biologics?” but rather “what’s the optimal sequence and combination?” For many patients, surgery followed by biologic therapy provides better outcomes than either alone, and for some — particularly those with mild to moderate disease, or those who haven’t yet maximized medical therapy — biologics may defer or prevent the need for surgery entirely.
The case for surgery as part of a combined strategy is mechanistically well-founded. Nasal polyps, by blocking sinus drainage and the olfactory cleft, prevent topical medications (intranasal steroids, saline irrigation) from reaching their target mucosa. FESS opens the sinuses, removes the polyp bulk, and creates anatomical conditions that dramatically improve the efficacy of postoperative medical management.
Post-FESS intranasal corticosteroid irrigations — using high-volume saline mixed with budesonide through the surgically opened sinus cavities — reach mucosal surfaces that were inaccessible before surgery and produce systemic corticosteroid exposure that’s minimal compared to oral dosing. The combination of FESS and ongoing medical management consistently outperforms either alone for symptom control and long-term disease management.
For patients with rapid polyp recurrence despite maximized medical therapy, or those requiring repeated surgical procedures, biologic therapy added to the postoperative regimen substantially reduces recurrence rates compared to surgery without biologics. A 2022 real-world analysis found that initiating dupilumab after FESS reduced the re-operation rate by approximately 60 percent over two years compared to patients who had surgery without subsequent biologic therapy.
The emerging paradigm: surgery to optimize anatomy and reduce disease burden, followed by ongoing biologic therapy to control the underlying inflammatory disease — each modality doing what it does best.
Eosinophilic Granulomatosis with Polyangiitis and Polyps
Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) is a rare systemic vasculitis that has nasal polyps and CRS as early manifestations, typically preceding the more serious organ involvement by years. EGPA follows a characteristic three-phase course: an allergic/atopic phase with asthma and nasal polyps; an eosinophilic phase with peripheral blood hypereosinophilia and eosinophilic tissue infiltration; and a vasculitic phase with granulomatous vasculitis affecting small and medium blood vessels in multiple organs.
The clinical relevance of EGPA in the context of nasal polyps: severe, treatment-refractory CRSwNP with severe asthma and elevated blood eosinophils should prompt consideration of EGPA, particularly alongside systemic symptoms (fever, weight loss, peripheral neuropathy, skin nodules, cardiac symptoms, renal involvement). The diagnostic criteria require systemic vasculitis features beyond the sinonasal and pulmonary disease — EGPA isn’t simply “severe CRSwNP” but a distinct systemic disease that happens to present with prominent sinonasal manifestations.
ANCA (anti-neutrophil cytoplasmic antibody) testing is positive in approximately 40 percent of EGPA cases. Treatment involves systemic corticosteroids and, in severe cases, cyclophosphamide or mepolizumab (which has FDA approval for EGPA).
Q&A About Nasal Polyps
Can nasal polyps become cancerous?
Inflammatory nasal polyps — the most common type, arising in the context of CRSwNP — are benign and have no malignant potential. They don’t transform into cancer. However, unilateral nasal polyps, polyps with unusual appearance (firm, vascular, friable rather than pale and compressible), polyps with associated bony destruction on imaging, or polyps that bleed easily on endoscopy should always get a tissue biopsy to exclude inverted papilloma (which can harbor or develop into squamous cell carcinoma) or primary sinonasal malignancy.
The standard recommendation: all polyp specimens removed during FESS should undergo histological examination, for exactly this reason.
Can diet reduce nasal polyps?
No dietary intervention has been shown in rigorous clinical trials to reduce nasal polyp burden or prevent recurrence. However, dietary salicylate restriction is recommended in AERD (aspirin-exacerbated respiratory disease) as an adjunct to aspirin desensitization therapy — AERD patients have elevated leukotriene production from multiple dietary salicylate sources in addition to NSAID use.
The omega-3 fatty acid pathway has mechanistic interest (EPA and DHA can produce anti-inflammatory eicosanoids through the 5-LOX pathway), and a small number of studies suggest omega-3 supplementation may modestly reduce leukotriene production in AERD. Vitamin D deficiency is associated with more severe CRSwNP in epidemiological studies, providing some rationale for maintaining adequate vitamin D status.
How long do the results of biologic therapy last?
Biologic therapy for CRSwNP requires ongoing maintenance — it’s not curative. When dupilumab or other biologics are discontinued, polyp recurrence typically begins within 3-6 months, with return to pre-treatment polyp scores within 12 months in most patients. The biologics suppress the underlying inflammatory disease while being administered; they don’t produce a lasting remission.
Patients with severe CRSwNP requiring biologic therapy need to understand this is long-term maintenance therapy — conceptually similar to insulin in diabetes: it controls the disease while taken but doesn’t cure the underlying condition. Some patients achieve durable partial remission with reduced but ongoing dosing; the optimal maintenance strategy for different biologic agents and patient phenotypes is an active area of clinical research.
Is it safe to use nasal corticosteroid sprays with polyps?
Yes. Intranasal corticosteroids are first-line treatment for CRSwNP, both before and after surgery. The key limitation is that polyps physically obstruct the spray’s access to the mucosal surface — large polyps significantly reduce topical delivery effectiveness because the medication can’t reach the inflamed mucosa behind and above the polyp mass.
Higher-volume delivery systems (irrigations rather than sprays) and positioning (tilting the head and rotating the spray to direct medication toward the middle meatus rather than along the floor of the nasal cavity) improve topical drug delivery in the presence of polyps. After surgical debulking, topical corticosteroid delivery improves dramatically and becomes more effective at maintaining the surgically improved anatomy.
What triggers rapid polyp recurrence after surgery?
Rapid polyp recurrence after surgery reflects inadequate control of the underlying type 2 inflammatory disease, not a failure of the surgery itself.
The strongest predictors of early recurrence: AERD (aspirin-exacerbated disease), elevated blood eosinophil count before surgery (higher eosinophilia correlates with faster recurrence), high tissue IgE, comorbid asthma (particularly severe or poorly controlled asthma), inadequate postoperative topical corticosteroid therapy, uncontrolled allergic rhinitis without allergen immunotherapy, ongoing tobacco smoking, and absence of biologic therapy in patients with the most severe disease.
The approach that most reliably reduces recurrence is treating the underlying inflammatory endotype — with biologics when appropriate — rather than simply repeating surgery on progressively scarring sinonasal anatomy.
Differential Diagnosis: What Looks Like Nasal Polyps But Isn’t
Not every lesion found in the nasal cavity is a benign inflammatory polyp, and the clinical consequences of misdiagnosis — particularly missing sinonasal malignancy — make proper diagnosis essential before any lesion is assumed to be a simple inflammatory polyp and managed accordingly. Several conditions mimic inflammatory polyps clinically and endoscopically but carry very different implications and management requirements.
Inverted papilloma (Schneiderian papilloma, transitional cell papilloma) is the most important differential diagnosis for a unilateral nasal polyp. It’s a benign but locally aggressive neoplasm arising from the Schneiderian membrane (the ectodermal mucosa lining the nasal cavity and paranasal sinuses), associated with human papillomavirus (HPV) infection in a significant proportion of cases, and carrying approximately a 10 to 15 percent risk of synchronous or metachronous squamous cell carcinoma.
Inverted papillomas typically appear on endoscopy as a unilateral, lobulated, rubbery mass, often on the lateral nasal wall near the middle turbinate. CT imaging characteristically shows a unilateral soft tissue mass with a cerebriform (brain-like) striated pattern on high-resolution scanning, often with bony remodeling rather than destruction. Complete surgical excision is required — simple polypectomy is inadequate given the tumor’s endophytic growth pattern and malignancy risk. HPV genotyping of the specimen guides surveillance intensity.
Angiofibroma — juvenile nasopharyngeal angiofibroma (JNA) — is a highly vascular benign tumor occurring almost exclusively in adolescent males, arising in the sphenopalatine foramen and extending into the nasal cavity and nasopharynx. The characteristic presentation is an adolescent male with unilateral nasal obstruction and recurrent epistaxis. The tumor is highly vascular and should never be biopsied in clinic — attempted biopsy of an unrecognized angiofibroma can precipitate life-threatening hemorrhage.
MRI characteristically shows a hypervascular mass with a “salt and pepper” appearance on gadolinium-enhanced imaging. Pre-operative embolization followed by surgical resection is the standard management.
Sinonasal malignancies — including squamous cell carcinoma, adenocarcinoma, sinonasal undifferentiated carcinoma, olfactory neuroblastoma (esthesioneuroblastoma), and lymphoma — can present as nasal masses mimicking polyps. Red flags for malignancy include unilaterality, facial pain (suggesting perineural invasion), diplopia or proptosis (orbital invasion), cheek hypoesthesia (V2 nerve involvement), trismus (pterygoid space involvement), loose teeth (alveolar invasion), and cervical lymphadenopathy.
Any nasal mass with atypical features — particularly unilateral location, vascular appearance, firm or friable consistency, or associated symptoms suggesting extranasal extension — requires tissue biopsy before any definitive management. Imaging (CT and MRI with contrast) before biopsy is appropriate to characterize the lesion and plan the biopsy approach safely.
Living With Nasal Polyps: Practical Strategies
Nasal polyps are a chronic condition requiring ongoing management, and adjusting to that reality — moving from expecting a cure to pursuing effective long-term disease control — is an important part of what patients need to understand.
The framework for living well with nasal polyps: a foundation of consistent medical management (intranasal corticosteroids, saline irrigation), appropriate biologic therapy when disease severity warrants it, regular monitoring of disease activity (through symptom tracking, olfactory testing, and periodic endoscopic evaluation), and prompt identification and management of exacerbating factors (respiratory infections, allergen exposures, aspirin/NSAID exposures in AERD).
Olfactory training — systematic repeated exposure to specific odorants (rose, lemon, cloves, eucalyptus) twice daily for months — has documented evidence for improving olfactory function in patients with post-inflammatory anosmia. The mechanism involves stimulating the neuroplasticity of olfactory receptor neurons and their central projections in the olfactory bulb, which can regenerate to a limited degree (olfactory receptor neurons turn over throughout life — among the only neurons in the mammalian nervous system that keep regenerating in adulthood).
Smell training is free, has no side effects, and has the best evidence for olfactory recovery of any non-pharmacological intervention available. It should be recommended to all CRSwNP patients with significant smell loss, as an adjunct to their primary management.
Air quality management at home — regular HEPA air filtration, avoiding indoor combustion (gas cooking, candles, incense, tobacco), maintaining optimal indoor humidity (40-60 percent, which optimizes mucociliary function and reduces mucosal dryness), and minimizing allergen exposure (through mattress and pillow encasements, high-frequency bedding washing, and pet allergen reduction in sensitized patients) — reduces the environmental inflammatory burden on the sinonasal mucosa.
These measures don’t replace primary medical management, but they reduce the drivers of ongoing mucosal inflammation that contribute to polyp formation and recurrence.
The psychological impact of chronic CRSwNP — including smell loss, sleep disruption, fatigue, and the frustration of recurrent disease despite treatment — deserves clinical attention it often doesn’t receive. Multiple studies using validated quality-of-life instruments have shown that the depression and anxiety burden in CRSwNP patients is substantial and correlates significantly with disease severity.
Treating the sinonasal disease effectively improves mood and quality of life — but in patients with significant psychological burden, specifically addressing anxiety and depression as comorbidities, rather than simply treating the sinonasal disease alone, produces better overall outcomes. The chronic disease management framework serving patients well here is the same one that serves any chronic condition: excellent medical management combined with realistic expectations and patient education that empowers active self-management.
The Microbiome and Nasal Polyps
Staphylococcus aureus is the organism most consistently associated with severe CRSwNP. S. aureus colonization rates in CRSwNP patients run substantially higher than in healthy controls or CRSsNP patients. The mechanisms linking S. aureus to polyp disease include superantigen production (described above), IL-31 and IFN-gamma induction (contributing to the inflammatory milieu), and direct epithelial barrier disruption. Multiple studies have found S. aureus colonization correlates with more severe endoscopy scores, higher tissue eosinophilia, and worse surgical outcomes.
Whether anti-staphylococcal strategies (targeted decolonization, anti-biofilm approaches) can improve CRSwNP outcomes is being studied, with some promising early results from S. aureus-targeted immunotherapy approaches in experimental models.
Probiotic approaches to sinonasal health — introducing beneficial bacterial species to the nasal microbiome to displace pathogenic colonizers — remain in very early research stages. Lactobacillus species, which produce lactic acid and bacteriocins that inhibit S. aureus growth, have been investigated in small clinical studies with preliminary signals of reduced S. aureus colonization and improved CRS symptom scores. Scientifically plausible, but this area needs much larger and more rigorously designed trials before any clinical recommendations can be made.
The conceptual parallel to gut microbiome therapeutics (probiotic and fecal transplant approaches for gastrointestinal conditions) is appealing, but the sinonasal environment is substantially different — smaller, more exposed to airborne challenges, and less tractable to microbiome modification through oral routes.
Nasal Polyps in Children: When It’s Not Routine
Nasal polyps in children are uncommon and warrant different clinical thinking than in adults. While CRSwNP is the most common cause of bilateral nasal polyps in adults, the differential in children looks different — specifically, nasal polyps in children should prompt systematic exclusion of cystic fibrosis before proceeding with routine management.
Cystic fibrosis affects approximately 1 in 3,000 live births in Northern European populations and is the most important cause of nasal polyps in children under 12. The CFTR protein defect in CF produces thick, dehydrated mucus that impairs mucociliary clearance in the sinonasal tract, promotes chronic infection, and drives the intense inflammatory response that generates polyps. Nasal polyps occur in approximately 40 to 50 percent of patients with CF, often presenting in middle childhood.
Sweat chloride testing should be performed in any child with nasal polyps under 12 years of age; a CF diagnosis radically changes the management approach, including consideration of CFTR modulator therapy, which can have dramatic effects on sinonasal disease alongside systemic CF manifestations.
Primary ciliary dyskinesia (PCD) — a genetic disorder of ciliary structure and function affecting mucociliary clearance throughout the respiratory tract — is another important pediatric cause of CRS with nasal polyps. PCD presents with recurrent respiratory infections, bronchiectasis, and CRS; approximately 50 percent of patients have situs inversus (mirror image arrangement of internal organs) due to the role of cilia in determining left-right organ laterality during embryonic development (Kartagener syndrome).
Nasal nitric oxide measurement — substantially reduced in PCD due to impaired ciliary function in nitric oxide synthesis — is a useful screening test. Genetic testing for PCD mutations provides definitive diagnosis. Management focuses on aggressive airway clearance therapy rather than polyp-specific approaches, because the fundamental problem is ciliary dysfunction rather than inflammatory polyp disease.
The Economic and Healthcare Burden of Nasal Polyps
The economic burden of nasal polyp disease — direct medical costs, indirect costs from lost productivity, and the costs of repeated surgical intervention — is substantial, and has been used to make the case for biologic therapy as cost-effective despite its high per-treatment cost.
A 2021 analysis in the Journal of Allergy and Clinical Immunology calculated that annual direct healthcare costs of CRSwNP in the US — physician visits, medications, surgical procedures — exceed $8 billion, with per-patient annual costs averaging several thousand dollars. Including indirect costs (work days lost to symptoms, reduced workplace productivity) expands the economic burden further.
The cost-effectiveness of biologic therapy in severe refractory CRSwNP depends critically on the patient’s prior surgical history and the incremental cost of additional surgery. For patients facing a third or fourth sinus surgery — with attendant direct costs, risks of cumulative surgical scarring, and recovery time — biologic therapy that eliminates the need for re-operation can be cost-competitive despite per-injection costs that look high in isolation.
Multiple cost-effectiveness analyses using quality-adjusted life year (QALY) frameworks have found dupilumab cost-effective at standard willingness-to-pay thresholds for patients with recurrent CRSwNP requiring repeated surgery, though the conclusion is sensitive to assumptions about surgery rates and biologic treatment duration.
The disease’s impact on workforce participation is significant and often invisible in healthcare cost analyses. Work impairment from nasal obstruction (reduced concentration, increased fatigue, reduced capacity for sustained cognitive effort) and from sleep disruption caused by CRSwNP is documented across multiple occupational health studies. Presentations, client meetings, and skilled work requiring sustained attention all suffer from the cognitive consequences of sleep disruption and chronic inflammation.
The “presenteeism” cost — productivity loss from employees who show up to work but function below capacity due to health conditions — consistently runs high for CRSwNP in workforce productivity analyses, often exceeding the absenteeism (days absent from work) cost.
The Role of Aspirin Desensitization in AERD
Aspirin desensitization therapy (ADT) for aspirin-exacerbated respiratory disease is one of the more counterintuitive therapeutic approaches in rhinology — administering increasing doses of the drug the patient is hypersensitive to, in a controlled setting, until tolerance is achieved and maintained. The scientific basis for its effectiveness is now well-established, and for motivated patients with AERD, it offers disease-modifying benefits no other available treatment provides.
The desensitization protocol begins with very low aspirin doses (typically 20-40 mg) administered under medical supervision with emergency resources available, then incrementally increased over two to three days until a full anti-inflammatory dose (325 mg or higher) is tolerated. The threshold at which the patient’s hypersensitivity reaction occurs — the dose triggering bronchospasm or rhinorrhea — gets crossed in the protocol, under controlled conditions.
After the threshold reaction is managed symptomatically, continued aspirin administration progressively desensitizes the reaction, achieving tolerance at higher doses. Once tolerance is established, continuous daily aspirin maintenance (1300 mg daily in two divided doses in most protocols) is required to maintain the desensitized state — stopping aspirin even briefly re-establishes hypersensitivity and requires repeating the desensitization.
The clinical benefits of maintained aspirin desensitization therapy extend well beyond allowing the patient to take aspirin. Randomized trials and large observational series have documented: significant reductions in nasal polyp burden (polyp score reductions of 35-50 percent), reduced need for rescue oral corticosteroids, improved sense of smell, improved asthma control, reduced frequency of asthma exacerbations, and reduced sinus surgery rates.
The mechanism appears to involve downregulation of the overactive 5-LOX pathway — specifically reducing the overproduction of cysteinyl leukotrienes that drives the AERD inflammatory phenotype — through mechanisms not fully elucidated but distinct from simple COX blockade. ADT is available at specialized centers and is an appropriate consideration for motivated AERD patients with significant polyp disease and asthma who understand the ongoing treatment commitment required.
The Practical Framework: Living With Nasal Polyps
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map